400 Shire Way
Lexington, MA 02421
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda’s R&D efforts are focused on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in Emerging Markets, are currently fueling the growth of Takeda. Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in approximately 80 countries. For more information, visit www.takeda.com.
Attendees will be visiting a 200,000 sq ft commercial and clinical state of the art manufacturing facility that utilizes a single-use platform. The tour highlights the Upstream and Downstream biotechnology related processes, and provides a better understanding of the approaches to implementation of the single-use platform and the effects that these have on production turnaround times and an increase of building efficiency. The facility is three level operation that houses bulk drug substance manufacturing operations, including Upstream, Downstream, Support Services and a JIT Warehouse. The facility is utilized for the manufacture of commercial products as well and launch of clinical products. The tour will consist of four stops in CNC: Inoculum Prep; Bioreactor Window (bioreactor/recovery ops); Media/Harvest Hold (support functions overview); and Purification Overview. The tour cadence will also allow for time to ask questions and gain input from area experts.
Tour Guidelines/Restrictions: Photos are not permitted. Full gowning will be required. Additional tour guidelines to follow after registration.
100 Tech Drive
Norwood, MA 02062
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca, Plc. and Merck, Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been ranked in the top ten of Science’s list of top biopharma industry employers for the past four years. To learn more, visit www.modernatx.com.
Participants will be given an overview by a representative from each are during a window tour of the automated and flexible Preclinical and Clinical Manufacturing suites. The overview will include digital infrastructure and integration. The tour will also include an overview of the design concepts related to the people spaces.
Tour Guidelines/Restrictions: Photos are not permitted. Comfortable, closed-toe walking shoes are recommended, as the tour will include stairs. Additional tour guidelines to follow after registration.